Ichor Life Sciences, Inc., founded in 2013, is a pioneering entity within the Biotechnology and Pharmaceutical industries. This company stands out as a trailblazer in the longevity biotechnology sector, leveraging its position as both an innovative venture studio and a comprehensive contract research organization (CRO).
The firm distinguishes itself by hosting the oldest longevity-focused PhD program aimed at drug discovery for age-related conditions. Within its venture studio, Ichor has developed a portfolio with four promising preclinical candidates targeting these diseases.
As a CRO, Ichor Life Sciences provides an expansive array of services including protein services, pharmacology, protocol design, and clinical trial site operations. This expertise not only facilitates client projects from inception to FDA approval but also accelerates advancements in anti-aging biotechnology.
In its latest financial activity, Ichor secured a $1.71M debt financing investment in September 2024, underpinning its ongoing contributions to biotech innovation and development.